GL Pharm Tech Corp.

Equities

A204840

KR7204840003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
1,225 ^KRW	-0.08%		-2.78%	+7.83%

05-03	An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	CI
03-06	W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund	CI

GL Pharm Tech Corp. announced that it has received KRW 3.1 billion in funding from Unione Communications Co., Ltd.

May 12, 2020

On May 13, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.

Latest news about GL Pharm Tech Corp.

An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	05-02	CI
W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund	03-05	CI
GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.	03-05	CI
GL Pharm Tech to Raise 9.2 Billion Won via Share Issuance; Shares Decline 7%	23-09-14	MT
GL Pharm Tech Corp. announced that it expects to receive KRW 9.199999458 billion in funding from W Science Co., Ltd.	23-09-13	CI
W Science Co., Ltd. agreed to acquire a 14.7% stake in GL Pharm Tech Corp.	23-09-13	CI
GL Pharm Tech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	23-03-16	CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	22-03-16	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 8.999999634 billion in funding from Ideal Private Equity Fund	20-11-22	CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	20-09-28	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	20-09-20	CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd.	20-08-11	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd.	20-07-28	CI
GL Pharm Tech Corp. announced that it has received KRW 3.1 billion in funding from Unione Communications Co., Ltd.	20-05-12	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 3.1 billion in funding from Unione Communications Co., Ltd. and other investors	20-05-06	CI
Crown Pharm Co., Ltd. announced that it has received KRW 1.00001 billion in funding from GL Pharm Tech Corp.	18-12-16	CI
Crown Pharm Co., Ltd. announced that it has received KRW 3.00003 billion in funding from GL Pharm Tech Corp.	18-05-22	CI
GL Pharm Tech Corp. announced that it has received KRW 7 billion in funding from Shinhan Investment Corp., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, E&INVESTMENT INC. and other investors	18-05-13	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 7 billion in funding from Shinhan Investment Corp., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, E&INVESTMENT INC., and other investors	18-05-10	CI
GL Pharm Tech Corp. completed the acquisition of remaining 67.91% stake in Crown Pharm Co., Ltd.	18-01-25	CI
GL Pharm Tech Corp. agreed to acquire remaining 67.91% stake in Crown Pharm Co., Ltd. for KRW 3 billion.	18-01-23	CI
Crown Pharm Co., Ltd. announced that it has received KRW 5.499740208 billion in funding from GL Pharm Tech Corp.	18-01-23	CI
GL Pharm Tech Corp. announced that it has received KRW 2 billion in funding from Daone Chemical Co., Ltd., Genebiotech Co., Ltd.	18-01-16	CI
GL Pharm Tech Corp. agreed to acquire a 32.1% stake in Crown Pharmaceutical Co., Ltd. from Seungho Shin for KRW 1.4 billion.	17-11-14	CI

Chart GL Pharm Tech Corp.

Duration

Period

More charts

Company Profile

GL Pharm Tech Corp., formerly IBKS No.2 Special Purpose Acquisition Company, is a Korea-based company mainly engaged in the research and development of pharmaceutical products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GL PHARM TECH CORP.	+7.83%	68.6M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research